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Breast cancer is the most common form of cancer 
in women worldwide. Altogether 6  224 cases were 
reported in South Africa (SA) in 2009.[1] Up to 10% 
of breast cancer cases are attributable to germline 
mutations in cancer susceptibility genes, leading to 
hereditary syndromes.[2] The most well described of these cancer 
syndromes is hereditary breast and ovarian cancer syndrome 
(HBOCS), which is an autosomal dominant inherited syndrome 
predisposing to several cancers, particularly those of the breast and 
ovaries. This syndrome is caused by the presence of heterozygous, 
pathogenic germline mutations in either the BRCA1 or BRCA2 genes.
Founder mutations (those that occur more frequently or almost 
exclusively in a specific founder population group) account for a 
significant proportion of BRCA mutations. One such example of a 
founder population is the SA Afrikaner population group, which 
dates back approximately 330 years, when European settlers arrived 
in what is now the Western Cape Province of SA. This population 
(of individuals primarily of Dutch, German and French ancestry) 
grew rapidly in the first century after arriving in SA, and as a result 
the mutations in the initial population increased in frequency. The 
outcome of these events can be seen in the large number of genetic 
conditions in which Afrikaner founder mutations are documented. [3] 
The Afrikaner population group, comprising 12.2% of individuals 
living in the Gauteng Province of SA,[4] has had three founder 
BRCA mutations identified to date that result in HBOCS: BRCA1 
c.1374delC, BRCA1 c.2641G>T and BRCA2 c.7934delG.[5-6]
The Division of Human Genetics at the National Health Laboratory 
Services (NHLS) and the University of the Witwatersrand (Wits) in 
Johannesburg, SA, has offered genetic counselling at clinics in 
various hospitals in the Johannesburg area since the 1970s. Afrikaner 
individuals with a personal or family history of breast and/or ovarian 
cancer are seen at these clinics. The role of the genetic counsellor 
in this setting is to provide information regarding the genetics of 
HBOCS and the risks of carrying and passing on a mutation, and 
to assist the counsellee in making informed decisions about genetic 
testing. Genetic counsellors consider a variety of factors when 
analysing each individual case. The family history of cancers, tumour 
histological features and age of onset of the cancers can influence 
risk assessment and decisions regarding genetic testing. There are 
also a number of risk assessment tools available to aid in the analysis 
of cases. The two tools widely used at the NHLS/Wits are the online 
Breast and Ovarian Analysis of Disease Incidence and Carrier 
Estimation Algorithm (BOADICEA) risk calculation program[7] and 
the revised Manchester scoring method.[8] Both prediction models 
calculate the likelihood of carrying a deleterious mutation in one of 
the BRCA genes. Although these tools were initially designed for use 
in European populations, studies have been performed to validate 
their uses in ethnically diverse populations.[9-10] This type of analysis 
has not been undertaken in the Afrikaner population of SA.
Once the appropriate analyses and risk assessments have been 
undertaken, the counsellee may be offered a molecular genetic test, 
including testing for the Afrikaner founder mutations as a first-
line testing option (prices range from approximately ZAR1 600 
to ZAR3 500). Following a negative founder mutation result, 
further molecular testing may be offered should the clinical and 
family history warrant it. These further tests include sequencing 
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of the BRCA1 and BRCA2 genes and large 
rearrangement analysis to detect large 
deletions/duplications (prices range from 
approximately ZAR9 000 to ZAR25 000). 
The range in prices for BRCA testing is 
laboratory dependent.
No formal guidelines currently exist to 
assist genetic counsellors or their counsellees 
in determining whether founder mutation 
analysis is sufficient or whether additional 
testing should be pursued following a 
negative result for the founder mutations 
identified in this population group.
Objectives
To conduct a retrospective file review of a 
cohort of Afrikaner individuals presenting 
for genetic counselling for HBOCS. The 
objectives were to: (i) investigate the uptake 
and type of molecular testing carried out; 
(ii) determine the prevalence of the founder 
and non-founder mutations identified in 
this cohort; and (iii) analyse the utility 
of two prediction models used in genetic 
counselling for inherited cancers.
Methods
A retrospective file review of all counsellees 
of self-reported Afrikaner ancestry who 
received genetic counselling for HBOCS 
in the genetic counselling clinics offered 
by the NHLS/Wits Division of Human 
Genetics in Johannesburg from August 2001 
to December 2014 was conducted. The files 
are maintained and archived at the Division 
of Human Genetics at the NHLS/Wits.
The specific counselling clinics were 
held at Charlotte Maxeke Johannesburg 
Academic Hospital, Chris Hani Baragwanath 
Academic Hospital, the Donald Gordon 
Medical Centre and Helen Joseph Hospital.
Subjects
Participants for the study were selected on 
the basis of the following criteria: at least one 
side of the family had to be of self-identified 
Afrikaner descent, and the family history of 
cancer had to be from the Afrikaner side of 
the family. All counsellees enrolled into the 
study were unrelated to one another.
The counsellee’s family history and demo -
graphic information was recorded and ana-
lysed. During a genetic counselling session 
the genetic counsellor discussed HBOCS and 
testing options with the counsellees. Clinical 
judgement alone has been used historically to 
categorise counsellees as having an average, 
moderate or high risk of having HBOCS. 
In more recent years, various tools and 
prediction models have been used to assist 
genetic counsellors in determining HBOCS 
risks.
Genetic counsellors at the NHLS/Wits 
calculate counsellees’ risks of carrying a 
dele terious BRCA1 or BRCA2 mutation 
using the online BOADICEA risk calculation 
program[7] and/or the Manchester scoring 
method.[8] The outputs of these tools were 
incorporated into the overall analysis of risk 
for each counsellee.
A data collection sheet was constructed to 
record the counsellees’ demographic infor-
mation, the specific tests undertaken, the 
cancers reported in the family and HBOCS 
risks given by the genetic counsellors, as well 
as risks calculated using BOADICEA and the 
revised Manchester scoring method for each 
individual. In cases where the BOADICEA or 
Manchester scores had not been calculated, 
these were computed from the pedigree data 
as part of the study for each counsellee (to 
obtain a pretesting risk output). These data 
allowed for standardised comparison among 
the different groups of counsellees.
Mann-Whitney tests were carried out to 
compare the BOADICEA and Manchester 
risk scores. The first was a comparison 
between counsellees who tested positive 
and negative for an Afrikaner founder 
mutation; this was done to evaluate whether 
the prediction models could be accurately 
applied to this population. The second 
comparison was carried out between those 
who tested positive and negative for a non-
founder mutation after further sequencing 
was done. A median BOADICEA risk score, 
given as a percentage chance of having a 
mutation, was then calculated for each 
group. The Manchester scores, given as 
whole numbers, correspond to the following 
risks: a score of >16 corresponds to a ≥10% 
chance of carrying a deleterious mutation 
and a score of ≥20 indicates a 20% chance of 
carrying a deleterious mutation.[11] As with 
the BOADICEA risk scores, the median 
Manchester scores for each group were 
calculated for comparison.
Once the counsellees were checked and 
found to be unrelated to one another, the 
data were anonymised in accordance with 
appropriate ethical protocols. Ethics clearance 
(reference: M101141) was obtained from the 
University of the Witwatersrand’s Human 
Research Ethics Committee (Medical).
Results
A total of 122 self-reported Afrikaner coun-
sellees were seen at the genetic counselling 
clinics for discussion around testing for 
HBOCS during the period 1 August 2001 - 
31 December 2014, and their files were 
available for review. Twenty were found 
to be related to others already included in 
the study, 4 were reported to have a family 
history of cancer on the non-Afrikaner 
side of their family, and a further 12 were 
excluded because insufficient information 
was provided. A total of 86 counsellees 
(70.5%) therefore matched the inclusion 
criteria specified for the study.
Of the 86 counsellees whose files were 
reviewed, 54 (62.8%) underwent BRCA 
Afrikaner founder mutation testing, and 
14/54 (25.9%) tested positive for one of 
the three founder mutations. Of the 40/54 
(74.1%) who tested negative for a founder 
mutation, only 10/40 (25.0%) opted for 
further analysis. Four of these 10 (40.0%) 
were found to carry a non-founder mutation 
(Fig. 1).
Total counsellees eligible for
inclusion in le review: N=86
Afrikaner counsellees
tested for founder
mutations: 54/86 (62.8%)
Afrikaner counsellees
not tested: 32/86 (37.2%)
Tested negative for
founder mutations:
40/54 (74.1%)
Counsellees oered
testing: 15/32 (46.8%)
Tested positive for
founder mutations:
14/54 (25.9%)
Counsellees not
oered testing:
17/32 (53.1%)
No further analysis:
30/40 (75.0%)
Continued to sequencing
and large rearrangement
analysis: 10/40 (25.0%)
Tested positive for
non-founder mutations:
4/10 (40.0%)
Tested negative for
non-founder mutations:
6/10 (60.0%)
Counsellees who did
not follow up:
14/15 (93.3%)
Aected relative
oered testing rst:
11/17 (64.7%)
Counsellees opting
not to test:
1/15 (6.7%)
HBOCS risk too
low: 6/17 (35.3%)
Fig. 1. Outline of testing options recommended and the outcomes for counsellees in this study (N=86).
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Of the 86 counsellees, 32 (37.2%) did not 
undergo any testing, although 15/32 (46.9%) 
were offered founder mutation testing. One 
counsellee opted not to undergo molecular 
testing for personal reasons, and 14 did 
not follow through with providing a blood 
sample for testing. The remaining 17/32 
(53.1%) were not offered testing, either 
because the risk for HBOCS was considered 
too low or because an affected relative who 
presented as a better candidate was offered 
testing.
Eighteen counsellees tested positive for 
a deleterious mutation in one of the BRCA 
genes, and 14 of these mutations (77.8%) 
were founder mutations in the Afrikaner 
population. The other four non-founder 
mutations identified were BRCA1 c.45dupT, 
BRCA1 c.181T>G, BRCA2 c.6621delA and 
BRCA2 c.6761_6762delTT. The Afrikaner 
BRCA2 c.7943delG founder mutation was 
the most common mutation in this cohort, 
with 12 of the 18 counsellees (66.7%) testing 
positive for it. The mutations found are 
summarised in Table 1.
A BOADICEA risk score and a 
Manchester score were calculated for 
each counsellee, based on personal and 
family history alone; molecular results 
were excluded from these calculations so 
that a pretest prediction of identifying a 
pathogenic BRCA mutation could be 
performed. Median scores and ranges for 
counsellees tested for the Afrikaner founder 
mutations were calculated, since the data did 
not follow a normal distribution (Table 2). 
A Mann-Whitney test was then carried out 
to examine whether or not the BOADICEA 
and Manchester prediction models were 
useful in this founder population. In order 
to compare the scores effectively, counsellees 
who tested positive for a founder mutation 
(n=14) were compared with counsellees 
who tested negative for a founder mutation 
(n=40). Significance was assumed at a one-
tailed p-value of <0.05. There was a highly 
significant difference in the BOADICEA risk 
scores for counsellees who tested positive 
and negative for an Afrikaner founder 
mutation (p<10-3); however, there was no 
significant difference in Manchester scores 
between the two groups (p=0.06). An outlier 
with a Manchester score of 106 who tested 
negative for an Afrikaner founder mutation 
and did not undergo further testing was 
removed from the group of counsellees. As a 
result, a significant difference was observed 
between the two groups (p=0.04).
Another Mann-Whitney test was con-
ducted on the 10 counsellees who opted 
for further testing after receiving a negative 
BRCA Afrikaner founder mutation result. 
They were divided into those who tested 
positive (n=4) and negative (n=6) for a BRCA 
mutation (Table 3). A significant difference 
in BOADICEA scores was observed between 
the two groups (p=0.04), but there was no 
significant difference in the Manchester 
score (p=0.07).
Discussion
According to the study data, the majority 
of the counsellees in this Afrikaner cohort 
(54/86, 62.8%) decided to undergo molecular 
genetic testing to detect a deleterious 
founder mutation in either of the BRCA 
genes. Among the counsellees who opted to 
undergo testing, the total mutation detection 
rate was 33.3% (18/54); 14 of these mutations 
(77.8%) were founder mutations prevalent in 
the Afrikaner population. Considering that 
a few of the counsellees who did not have 
molecular testing were also considered to be 
at a high risk for HBOCS, this detection rate 
has the potential to be even higher.
The most common mutation detected 
in this cohort was the BRCA2 c.7934delG 
Afrikaner founder mutation, which was 
identified in 12 counsellees (22.2% of those 
tested). The other two Afrikaner founder 
mutations (BRCA1 c.1374delC and BRCA1 
c.2641G>T) occurred only once each, which 
is less than expected. The reason for this 
distribution is unclear, but may represent a 
geographical variation. In the original article 
describing these two mutations, five families 
with the c.2641G>T mutation and two 
families with the c.1374delC mutation were 
reported in a cohort made up of 90 individuals 
from various population groups. [5] The 
authors stated that after their article was 
completed, an additional eight families were 
identified as having the c.2641G>T mutation 
and a further two families were reported to 
have the c.1374delC mutation.
The four non-founder mutations were 
identified only once each. The BRCA1 
c.181T>G mutation is a European founder 
mutation. [11] The other three non-founder 
mutations (BRCA1 c.45dupT, BRCA2 
c.6621delA and BRCA2 c.6761_6762delTT) 
have not been reported in the literature 
before. BRCA1 c.45dupT has been identified 
during BRCA1/2 molecular testing in labora-
Table 1. Frequencies of BRCA1 and BRCA2 mutations identified in the Afrikaner cohort (N=18)
Gene Mutation Counsellees who tested positive, n (%)
BRCA1 c.45dupT 1 (5.5)
c.181T>G 1 (5.5)
c.1374delC* 1 (5.5)
c.2641G>T* 1 (5.5)
BRCA2 c.6621delA 1 (5.5)
c.6761_6762delTT 1 (5.5)
c.7934delG* 12 (67.0)
*The three founder mutations previously identified in the Afrikaner population of SA.
Table 2. Median pretesting BOADICEA and Manchester risk scores for counsellees 
tested for Afrikaner founder mutations in the BRCA genes (N=54)
Risk score, median (range)
Risk assessment tool
Counsellees who tested positive 
for a founder mutation (n=14)
Counsellees who tested negative 
for a founder mutation (n=40)
BOADICEA, % 35.6 (8.2 - 91.6) 5.6 (0.5 - 93.2)
Manchester score 21 (16 - 40) 16.5 (6 - 42)*
*An outlier with a Manchester score of 106 was excluded.
Table 3. Median pretesting BOADICEA and Manchester risk scores for counsellees 
who underwent further BRCA analysis (N=10)
Risk assessment tool
Risk score, median (range)
Counsellees who tested positive 
for a non-founder mutation
(n=4)
Counsellees who tested negative 
for a non-founder mutation
(n=6)
BOADICEA, % 44.6 (2.7 - 74.3) 3.15 (0.9 - 19.0) 
Manchester score 24.5 (16 - 32) 15.5 (8 - 28)
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tories around SA (Dr Nico de Villiers, personal communication) and 
the BRCA2 c.6761_6762delTT mutation has been reported in the 
National Centre for Biotechnology Information, ClinVar database. [12] 
Further studies, including haplotype analysis around the mutation 
region, are needed to characterise BRCA1 c.45dupT in SA.
Fifteen of the counsellees who were offered testing did not pursue 
it (17.4%). This raises concern. Counsellees who could potentially 
be carrying deleterious mutations are not being tested and would 
therefore not benefit from prevention strategies.
A study by Petrucelli et al.[13] on the Ashkenazi Jewish population 
of Michigan found that only 1 out of 166 (0.6%) had a non-founder 
BRCA1/2 mutation.[13] The authors observed that the National 
Comprehensive Cancer Network recommends further molecular 
analysis following a negative founder mutation result only when there 
is evidence of non-Ashkenazi Jewish ancestry. Even though only a 
small number of counsellees from the current study opted for further 
analysis when initial founder mutation testing was negative, 40% 
(4/10) had a non-founder mutation, which is a higher proportion 
than reflected in Petrucelli et al.’s research. This suggests that, in 
the Afrikaner population of SA, further analysis is required more 
frequently than suggested by Petrucelli et al.
Mutation prediction models have been useful in recent years to 
assist genetic counsellors in deciding whether or not to offer their 
clients further analysis. Prediction models of this kind have been 
validated in various ethnic groups,[9-10] but have not yet been modified 
to account for founder mutations in populations such as the SA 
Afrikaner population. Comparison of the two prediction models 
in the present study has revealed that the BOADICEA prediction 
model seems to discriminate high-risk individuals better than the 
Manchester model. Even though the numbers were small, there was a 
significant difference in the BOADICEA scores between counsellees 
who tested positive and negative upon further BRCA analysis. 
This indicates that, following a negative founder result, BRCA 
sequencing and deletion/duplication analysis should be pursued if 
the BOADICEA score is >10%. The application of this threshold 
could reduce unnecessary costs if further testing is not pursued. 
Further studies are necessary in larger samples to examine the role of 
these prediction models comprehensively in the Afrikaner founder 
population. However, in this study, the BOADICEA prediction model 
provided a good additional indication as to whether or not further 
testing was warranted.
Conclusions
The findings of this study have shown that 54/86 Afrikaner 
counsellees underwent BRCA testing in the Johannesburg area over 
the period 2001 - 2014. Insight is provided into the prevalence of 
BRCA founder mutations in the local Afrikaner population. The 
sample in the present study may not be representative of the wider 
Afrikaner population in the country, and further analysis of samples 
from at-risk families living elsewhere may indicate a need for 
regional-specific practice.
The presence of four non-founder mutations in the study cohort 
suggests that screening for founder mutations alone in high-risk 
counsellees may be insufficient. Clinical judgement and appropriately 
assessed prediction tools should be used to determine the most 
cost-effective course of testing and which counsellees would benefit 
from full sequencing and deletion/duplication analysis after a 
negative founder screen. A similar analysis to that described here, but 
performed on a larger sample, would provide more comprehensive 
results. Efforts in this regard are ongoing locally.
While the BOADICEA and Manchester risk prediction models 
were not designed to take into account founder mutations for the 
Afrikaner population, it is evident that these prediction models are 
very useful in this population. Genetic counsellors should be encour-
aged to utilise these models to aid in decision-making regarding test-
ing for BRCA mutations. A high BOADICEA score would support 
further BRCA testing if the founder mutation screen is negative.
Genetic counsellors in SA need to be cognisant of the Afrikaner 
founder mutations and their possible presence in ethnic groups 
that may have Afrikaner admixture, and testing options should be 
considered accordingly.
The use of a retrospective, file-based approach limited this study 
to an analysis of the information contained in the counsellees’ files. 
Further studies of a prospective and qualitative nature, could obtain 
insight into the attitudes and perceptions of Afrikaner counsellees 
regarding the process of genetic counselling and decision-making 
with regard to BRCA testing.
The findings from this study will be useful in the provision of an 
informed genetic counselling service to at-risk individuals with an 
Afrikaner background in an SA setting. This research illustrates the 
necessity of genetic counselling and testing of appropriate patients. 
Patients with a family history of breast and/or ovarian cancer, women 
<50 years of age with breast cancer, males with breast cancer and 
families with cancer from high-risk ethnic groups such as Afrikaners 
and Ashkenazi Jews should be referred for genetic counselling.
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